A Phase II Clinical Study of PDC-748 in Patients With Acute Cough
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
The pharmacological effects of PDC-748 were tested in numerous in vitro and in vivo studies.
The existing pharmacologic findings suggest that PDC-748 possesses certain inhibitory
activity to the citric acid- and capsaicin-induced cough reflex in guinea pigs with a
dose-dependent manner. Furthermore, a previous Phase I/II uncontrolled, dose-escalating study
has shown PDC-748 to be well tolerated and may help to alleviate daytime cough with a
dose-responding manner.Hence, PhytoHealth Corporation intends to carry out a Phase II
investigation to confirm the preliminary findings using placebo in the comparator group, and
to further investigate PDC-748 with a dose escalating manner to establish the dose-response
range for its antitussive effect, and if possible, to determine the maximal tolerable dose of
PDC-748.
This is a randomized, double-blind, placebo-controlled, dose escalating study to evaluate the
safety and efficacy of the escalating dose levels of PDC-748 in patients with acute cough.